Background: Clinical drugs for herpesvirus exhibit high toxicity and suffer from significant
drug-resistance. The development of new, effective, and safe anti-herpesvirus agents with
different mechanisms of action is greatly required.
Objective: Novel inhibitors against herpesvirus with different mechanisms of action from that of
Methods: A series of novel 5-(benzylamino)-1H-1,2,3-triazole-4-carboxamides were efficiently
synthesized and EC50 values against human cytomegalovirus (HCMV), varicella-zoster virus
(VZV) and herpes simplex virus (HSV) were evaluated in vitro.
Results: Some compounds present antiviral activity. Compounds 5s and 5t are potent against both
HCMV and VZV. Compounds 5m, 5n, 5s, and 5t show similar EC50 values against both TK+ and
TK- VZV strains.
Conclusion: 5-(Benzylamino)-1H-1, 2,3-triazole-4-carboxamides are active against herpesviruses
and their activity is remarkably affected by the nature and the position of substituents in the benzene
ring. The results indicate that these derivatives are independent of the viral thymidine kinase
(TK) for activation, which is indispensable for current drugs. Their mechanisms of action may differ
from those of the clinic anti-herpesvirus drugs.